Skip Navigation


JAC Advance Access originally published online on November 3, 2006
Journal of Antimicrobial Chemotherapy 2007 59(1):160-161; doi:10.1093/jac/dkl449
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
59/1/160    most recent
dkl449v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Latifi-Navid, S.
Right arrow Articles by Massarrat, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Latifi-Navid, S.
Right arrow Articles by Massarrat, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Correspondence

Antimicrobial effectiveness of ketoconazole against metronidazole-resistant Helicobacter pylori isolates from Iranian dyspeptic patients

S. Latifi-Navid1, F. Siavoshi1, F. Safari1, R. Malekzadeh2 and S. Massarrat2

1 Microbiology Department, Faculty of Sciences, University of Tehran Tehran, Iran 2 Digestive Diseases Research Centre, Tehran University of Medical Sciences Tehran, Iran

*Corresponding author. Tel: +98-2161112460; Fax: +98-2166405141; E-mail: siavoshi@khayam.ut.ac.ir

Keywords: antimycotics , oral yeasts , dual activity

The first 10% of the full text of this article appears below.

Sir,

The rate of Helicobacter pylori infection in Iran reaches up to 85% and a considerable proportion of infected individuals develop gastric diseases.1 Furthermore, the eradication rate of H. pylori infection is low, mainly due to a considerable number (37%) of metronidazole-resistant strains.2 Accordingly, investigators have been trying to substitute this antibiotic. Since fatty acids, namely cholesteryl glucosides, have been found in the cell membrane of Helicobacter species, investigators have speculated that imidazole antimycotics such as ketoconazole might interfere with the biosynthesis of these fatty . . . [Full Text of this Article]

Transparency declarations


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?